Bayesian Applications in Pharmaceutical Development
-10%
portes grátis
Bayesian Applications in Pharmaceutical Development
Natanegara, Fanni; Lakshminarayanan, Mani
Taylor & Francis Ltd
10/2019
532
Dura
Inglês
9781138296763
15 a 20 dias
1140
Descrição não disponível.
Introduction. Building prior. Discover/preclinical phase. Clinical phase. Product development. Regulatory overview of Bayesian application. Computational tools. Special topics.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
MMRM;MMRM Analysis;drug development;Bayesian Predictive Probabilities;quantitative evaluation;PoC Study;prior distribution;Posterior Distribution;health care;Data Monitoring Committees;decision making;Interim Analysis;clinical trials;Posterior Predictive Distribution;Bayesian applications;Bayesian Sample Size Determination;drug development process;Non-informative Prior;innovative trial designs;PASI75 Response;pharmaceutical development;Prior Distributions;Bayesian Adaptive Design;Target DLT Rate;Unchallenged Group;Adaptive Randomization;Regulatory Reviewers;Prior Information;Adaptive Design;Drug Combination Trials;Effective Sample Size;Study Ii;Missing Data;SMA Type;DLT Rate
Introduction. Building prior. Discover/preclinical phase. Clinical phase. Product development. Regulatory overview of Bayesian application. Computational tools. Special topics.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
MMRM;MMRM Analysis;drug development;Bayesian Predictive Probabilities;quantitative evaluation;PoC Study;prior distribution;Posterior Distribution;health care;Data Monitoring Committees;decision making;Interim Analysis;clinical trials;Posterior Predictive Distribution;Bayesian applications;Bayesian Sample Size Determination;drug development process;Non-informative Prior;innovative trial designs;PASI75 Response;pharmaceutical development;Prior Distributions;Bayesian Adaptive Design;Target DLT Rate;Unchallenged Group;Adaptive Randomization;Regulatory Reviewers;Prior Information;Adaptive Design;Drug Combination Trials;Effective Sample Size;Study Ii;Missing Data;SMA Type;DLT Rate
